NCT06058793已完成3 期
Brightline-4: A Phase III Open-label, Single-arm, Multi-center Study to Assess the Safety and Efficacy of Brigimadlin (BI 907828) Treatment in Patients With Treatment-naïve or Pre-treated Advanced Dedifferentiated Liposarcoma
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 138
- 试验地点
- 106
- 主要终点
- Occurrence of TEAEs with Grade ≥3 according to CTCAE version 5 during the entire treatment period
研究概览
简要总结
This study is open to adults with a type of cancer called dedifferentiated liposarcoma (DDLPS). They can join the study if their tumours are positive for MDM2. The purpose of this study is to find out whether a medicine called brigimadlin (BI 907828) is tolerated by and helps people with DDLPS. Brigimadlin is a so-called MDM2 inhibitor that is being developed to treat cancer.
Participants take brigimadlin as a tablet once every 3 weeks. Participants may continue to take brigimadlin as long as they benefit from treatment and can tolerate it. They visit the study site regularly. At the study site, doctors regularly check participants' health and take note of any unwanted effects. The doctors also regularly check tumour size.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Provision of signed and dated, written informed consent form (ICF) in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) - Good Clinical Practice (GCP) and local legislation prior to any study-specific procedures, sampling, or analyses
- •Male or female patients ≥18 years old at the time of signature of the ICF
- •Women of childbearing potential (WOCBP) and men able to father a child must be ready and able to use two medically acceptable methods of birth control per ICH M3 (R2) that result in a low failure rate of <1% per year when used consistently and correctly beginning at screening, during study participation, and until 6 months and 12 days after last dose for women and 102 days after last dose for men. A list of contraception methods meeting these criteria is provided in the patient information
- •Histologically documented locally advanced or metastatic, unresectable (i.e. surgery morbidity would outweigh potential benefits), progressive or recurrent Dedifferentiated liposarcoma (DDLPS), meeting the criteria for an open study cohort:
- •Cohort A: patient has not received prior systemic therapy for DDLPS in any setting (including adjuvant, neoadjuvant, maintenance, palliative)
- •Cohort B: patient has received any prior systemic therapy for DDLPS in any setting (including adjuvant, neoadjuvant, maintenance, palliative)
- •Written pathology report indicating the diagnosis of DDLPS with positive MDM2 immunohistochemistry or MDM2 amplification as demonstrated by fluorescence in situ hybridisation (FISH) or next-generation sequencing (NGS)
- •Presence of at least 1 measurable target lesion according to RECIST version 1.
- •In patients who only have 1 target lesion, the baseline imaging must be performed at least 2 weeks after any biopsy of the target lesion
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- •Life expectancy ≥3 months at the start of treatment in the opinion of the investigator Further inclusion criteria apply.
排除标准
- •Known mutation in the TP53 gene (screening for TP53 status is not required)
- •Major surgery (major according to the investigator's assessment) performed within 4 weeks prior to start of study treatment or planned within 6 months after screening
- •Previous administration of brigimadlin or any other MDM2-p53 or MDM4 regulator of p53 (MDM4/MDMX)-p53 antagonist
- •Previous treatment in study 1403-0008 (Brightline-1)
- •Having to receive, or intending to receive, restricted medications or any drug considered likely to interfere with the safe conduct of the study
- •Receiving treatment for brain metastases or leptomeningeal disease (LMD) which may interfere with safety and/or endpoint assessment
- •Unable to swallow the study treatment
- •Previous or concomitant malignancies other than the one treated in this study within the previous 2 years, except effectively treated non-melanoma skin cancers, carcinoma in situ of the cervix, ductal carcinoma in situ, or other malignancy that is considered cured by local treatment Further exclusion criteria apply.
研究组 & 干预措施
Brigimadlin treatment
Experimental
干预措施: Brigimadlin (Drug)
结局指标
主要结局
Occurrence of TEAEs with Grade ≥3 according to CTCAE version 5 during the entire treatment period
时间窗: up to 23 months
Occurrence of Treatment-emergent adverse events (TEAEs) according to Common Terminology Criteria for Adverse Events (CTCAE) version 5 during the entire treatment period
时间窗: up to 23 months
次要结局
- Occurrence of treatment-emergent serious adverse events (SAEs)(up to 23 months)
- Occurrence of TEAEs leading to study treatment discontinuation(up to 23 months)
- Occurrence of TEAEs leading to dose reduction(up to 23 months)
- Occurrence of TEAEs leading to dose delay(up to 23 months)
- Occurrence of TEAEs of special interest (adverse events of special interest [AESIs])(up to 23 months)
- Objective response (OR)(up to 23 months)
- Progression-free survival (PFS)(up to 23 months)
- Overall survival (OS)(up to 23 months)
- Duration of objective response (DOR)(up to 23 months)
- Disease control (DC)(up to 23 months)
研究者
研究点 (106)
Loading locations...
相似试验
已完成
2 期
Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated LiposarcomaLiposarcoma, DedifferentiatedNCT05218499Boehringer Ingelheim400
撤回
3 期
Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue SarcomaAdvanced Soft Tissue SarcomaUndifferentiated Pleomorphic Sarcoma (UPS)Myxofibrosarcoma (MFS)NCT06370871Boehringer Ingelheim
进行中（未招募）
1 期
DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent ChemotherapySmall Cell Lung Carcinoma (SCLC)NCT05990738Boehringer Ingelheim69
终止
4 期
Efficacy and Safety of PLACENTEX ® i.m. in Patients With Scleroderma DiseasesScleroderma DiseaseNCT03388255Mastelli S.r.l25
进行中（未招募）
3 期
Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLCNon-Small Cell Lung CancerNCT06031558Shouyao Holdings (Beijing) Co. LTD120